The rationale and methodology of CGM (iPro2 and Enlite Glucose Sensor; Medtronic, Tolochenaz, Switzerland) have been described previously [14 (link)]. In brief, the CGM device was worn abdominally and recorded subcutaneous interstitial glucose values (range: 2.2–22.2 mmol/L) every five minutes for a seven-day period. For calibration purposes, participants were asked to perform self-measurements of blood glucose four times daily (Contour Next; Ascensia Diabetes Care, Mijdrecht, the Netherlands). Participants were blinded to the CGM recording, but not to self-measured values. Diabetes medication use was allowed and no dietary instructions were given. We only included individuals with at least 48h of CGM, but excluded the first 24h of CGM from analysis because of insufficient calibration. For the glucose prediction analyses, all remaining glucose data points were used. We additionally calculated mean sensor glucose, standard deviation (SD), and coefficient of variation (CV) with the use of Glycemic Variability Research Tool (GlyVaRT; Medtronic) software.
Glyvart
Manufactured by Medtronic
GlyVaRT is a laboratory equipment product designed for the analysis and detection of glycoproteins. It is a versatile tool that employs advanced techniques to facilitate the identification and characterization of glycosylated proteins. The core function of GlyVaRT is to enable researchers and scientists to analyze the structure and composition of glycoproteins, which play a crucial role in various biological processes.
Automatically generated - may contain errors
2 protocols using glyvart
1
Continuous Glucose Monitoring Protocol
2
Comparison of CIPII and SC Insulin
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Results were expressed as mean (with SD) or median (with interquartile range) for normally distributed and non-normally distributed data, respectively. A significance level of 5% (twosided) was used. Normality was examined with Q-Q plots. A regression model based on covariate analysis was applied in order to take possible baseline imbalance into account. In the model the fixed factors CIPII and SC insulin therapy were used as determinants. The difference in scores was determined based on the b coefficient of the particular (CIPII or SC) group. Significance of the b coefficient was investigated with the Wald test based on P < 0.05. The quantity of the b coefficient, with a 95% confidence interval (CI), gives the difference between both treatment modalities over the study period adjusted for baseline differences. Statistical analyses were performed using SPSS software (IBM SPSS Statistics for Windows, version 20.0; IBM Corp., Armonk, NY). CGM data were processed using the GV calculation tool (GlyVarT; Medtronic).
The study protocol was approved by the local medical ethics committee, and all patients gave informed consent.
The study protocol was approved by the local medical ethics committee, and all patients gave informed consent.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!